US · VTVT
vTv Therapeutics Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- High Point, NC 27265
- Website
- vtvtherapeutics.com
Price · as of 2024-12-31
$31.69
Market cap 99.87M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | $6.16 | -80.56% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | $0.00 | $0.00 | |||
| 2015 | $245.20 | $98.59 | $0.00 | $0.00 | $7,360.15 |
| 2016 | $232.40 | $95.60 | $0.00 | $0.00 | $0.00 |
| 2017 | $256.80 | $135.74 | $0.00 | $0.00 | $2,912.16 |
| 2018 | $83.60 | $1,430.92 | $6,128,648.93 | $0.00 | $0.00 |
| 2019 | $123.20 | $125.64 | $283.42 | $0.00 | $1,920.24 |
| 2020 | $108.00 | $231.59 | $159,240.25 | $0.00 | $0.00 |
| 2021 | $20.28 | $8.11 | $0.92 | $0.00 | $230.81 |
| 2022 | $28.76 | $86.97 | $0.00 | $0.00 | $392.44 |
| 2023 | $14.54 | $12.51 | |||
| 2024 | $15.39 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates vTv Therapeutics Inc.'s (VTVT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $31.69
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$6.16
-80.56% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| VTVT | vTv Therapeutics Inc. | $31.69 | 99.87M | — | -81% | — | — | -3.91 | 7.28 | 87.34 | -2.32 | — | 7.28 | 100.00% | -2377.58% | -1815.34% | 363.83% | 83.42% | -92.14% | 0.01 | — | 7.34 | 7.08 | 1.62 | -6704.00% | — | 3263.00% | -28.49% | -4.87 | 87.30% | 0.00% | 0.00% | 31.14% | -2.16 | -2.06 | 51.37 | -9.77 |
| CRVO | CervoMed Inc. | $3.99 | 36.92M | — | — | — | — | -1.10 | 0.46 | — | 1.16 | -0.75 | 0.46 | 0.00% | — | — | -69.95% | 26851.40% | -61.41% | 0.00 | — | 11.11 | 10.61 | 0.49 | 14634.00% | — | 12189.00% | -92.65% | -4.26 | 24352.48% | 0.00% | 0.00% | 6.76% | 1.16 | 1.28 | — | 0.16 |
| FBIO | Fortress Biotech, Inc. | $3.42 | 106.15M | +410% | -82% | — | +1,342% | -0.26 | 1.41 | 0.55 | -0.49 | — | -3.51 | 63.80% | -191.38% | -79.75% | -533.80% | -308.14% | -77.53% | 3.34 | -11.12 | 1.27 | 0.95 | -0.18 | -6824.00% | -3176.00% | -3017.00% | -297.40% | -1.12 | -265.74% | 14.72% | -3.90% | 14.72% | -0.46 | -0.53 | 0.88 | -9.03 |
| GANX | Gain Therapeutics, Inc. | $2.61 | 100.39M | +1,143% | — | — | — | -2.11 | 5.86 | — | -1.64 | — | 5.97 | 0.00% | — | — | -204.95% | 729.11% | -132.83% | 0.09 | — | 2.97 | 2.85 | 0.48 | -4795.00% | -10000.00% | 8.00% | -43.93% | -4.83 | 677.01% | 0.00% | 0.00% | 0.00% | -1.64 | -1.76 | — | -8.76 |
| HOWL | Werewolf Therapeutics, In… | $0.60 | 29.13M | +4,114% | — | — | +21,192% | -0.76 | 0.73 | 28.28 | 0.32 | -1.37 | 0.73 | 3.77% | -3904.19% | -3740.85% | -76.33% | -517.61% | -46.74% | 0.51 | -15.81 | 7.45 | 7.31 | 1.15 | 5524.00% | -9055.00% | 6908.00% | -105.90% | -3.70 | -396.98% | 0.00% | 0.00% | 0.00% | 0.28 | 0.37 | -10.93 | -4.95 |
| INKT | MiNK Therapeutics, Inc. | $10.95 | 51.4M | — | — | — | — | -2.85 | -1.57 | — | -2.94 | — | -1.57 | 0.00% | — | — | 57.30% | 52.39% | -209.96% | -0.25 | — | 0.72 | 0.66 | -0.03 | -5719.00% | — | -3966.00% | -31.13% | -1.37 | 47.00% | 0.00% | 0.00% | 0.00% | -2.92 | -3.25 | — | -41.11 |
| IOBT | IO Biotech, Inc. | $0.35 | 25.11M | — | — | — | — | -0.62 | 1.26 | — | -0.01 | — | 1.26 | 0.00% | — | — | -106.00% | 1021.32% | -87.44% | 0.04 | — | 3.33 | 3.14 | 0.62 | -2677.00% | — | 1434.00% | -138.96% | -4.23 | 884.12% | 0.00% | 0.00% | 0.00% | -0.01 | -0.01 | — | -9.54 |
| NRXP | NRx Pharmaceuticals, Inc. | $1.86 | 32.15M | — | — | — | — | -0.91 | -0.98 | — | -1.16 | — | -0.98 | 0.00% | — | — | 143.76% | 156.03% | -458.25% | -0.28 | -18.26 | 0.15 | 0.07 | -0.21 | -3995.00% | — | -5089.00% | -46.61% | -0.49 | 84.23% | 0.00% | 0.00% | 0.00% | -1.42 | -2.63 | — | -130.11 |
| OTLK | Outlook Therapeutics, Inc… | $0.42 | 17.31M | — | +90,898,778% | — | — | 0.00 | 0.00 | 50.46 | 123242.30 | — | 0.00 | 46.49% | -4744.25% | -4416.22% | 387.88% | 0.00% | -671.81% | -0.01 | -236.86 | 0.38 | 0.18 | 123243.42 | -5591.00% | — | 7534010988.00% | -72659652.79% | -1.13 | 259.00% | 0.00% | 0.00% | 10984444.51% | 116837.47 | 0.15 | -5543064.49 | -47.47 |
| SPRB | Spruce Biosciences, Inc. | $54.94 | 31.88M | +1,366% | +1,346% | — | +7,284% | -20.08 | 36.96 | 216.90 | -19.54 | -498.08 | 36.96 | 100.00% | -1143.37% | -1079.94% | -100.70% | 501.62% | -71.12% | 0.10 | -182.90 | 2.90 | 2.54 | 0.68 | 403.00% | -5132.00% | 6815.00% | -5.25% | -3.67 | 499.95% | 0.00% | 0.00% | 0.00% | -18.33 | -18.39 | 209.57 | 28.03 |
About vTv Therapeutics Inc.
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
- CEO
- Paul J. Sekhri
- Employees
- 23
- Beta
- 0.46
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($6.16 ÷ $31.69) − 1 = -80.56% (DCF, example).